Selective Targeting and Tissue Penetration to the Retina by a Systemically Administered Vascular Homing Peptide in Oxygen Induced Retinopathy (OIR)

Pathological angiogenesis is the hallmark of ischemic retinal diseases among them retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (PDR). Oxygen-induced retinopathy (OIR) is a pure hypoxia-driven angiogenesis model and a widely used model for ischemic retinopathies. We explore...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2021-11, Vol.13 (11), p.1932
Main Authors: Vähätupa, Maria, Salonen, Niklas, Uusitalo-Järvinen, Hannele, Järvinen, Tero A. H.
Format: Article
Language:English
Subjects:
Angiogenesis
Bioavailability
Blood vessels
cell penetrating peptide
Diabetic retinopathy
Disease
Hypoxia
Localization
Medical research
oxygen-induced retinopathy (OIR)
Peptides
Permeability
Retina
Transcription factors
Vascular endothelial growth factor
vascular homing peptide
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pathological angiogenesis is the hallmark of ischemic retinal diseases among them retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (PDR). Oxygen-induced retinopathy (OIR) is a pure hypoxia-driven angiogenesis model and a widely used model for ischemic retinopathies. We explored whether the vascular homing peptide CAR (CARSKNKDC) which recognizes angiogenic blood vessels can be used to target the retina in OIR. We were able to demonstrate that the systemically administered CAR vascular homing peptide homed selectively to the preretinal neovessels in OIR. As a cell and tissue-penetrating peptide, CAR also penetrated into the retina. Hyperoxia used to induce OIR in the retina also causes bronchopulmonary dysplasia in the lungs. We showed that the CAR peptide is not targeted to the lungs in normal mice but is targeted to the lungs after hyperoxia-/hypoxia-treatment of the animals. The site-specific delivery of the CAR peptide to the pathologic retinal vasculature and the penetration of the retinal tissue may offer new opportunities for treating retinopathies more selectively and with less side effects.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics13111932